WPC Banner  

Imaging in Preclinical and First in Human Clinical Studies in Oncology

Imaging remains an important tool in oncology drug discovery and development. This non-invasive technology delivers significant time and cost reduction when used systematically and skillfully. Cambridge Healthtech’s Fifth Annual Imaging in Preclinical and First in Human Clinical Studies in Oncology is designed to bring together leading imaging experts from industry and academia, as well as scientists who use their services to accelerate cancer research.

Day 1 | Day 2 | Oncology Brochure 

Wednesday, May 21

7:00 am Registration and Morning Coffee


8:00 Chairperson’s Opening Remarks

Erik M. Shapiro, Ph.D., Research Director, Department of Radiology, Michigan State University

8:05 FEATURED PRESENTATION: Image-Guided Surgery and Pathology Using Invisible Near-Infrared Fluorescent Light

John FrangioniJohn V. Frangioni, M.D., Ph.D., Professor, Department of Medicine and Radiology, Harvard Medical School

Near-infrared light in the wavelength range of 700-900 nm has relatively low attenuation and autofluorescence, permitting interrogation up to 5 mn below the surface of living tissue. In this talk, I will highlight the use of near-infrared fluorescent light for image-guided surgery and automated digital pathology, and review the clinical studies to date in the field.

8:35 Advances in Molecular and Cellular MRI

Erik ShapiroErik M. Shapiro, Ph.D., Research Director, Department of Radiology, Michigan State University

This presentation will cover: MRI contrast agents for Molecular and Cellular MRI; Strategies for using targeted contrast agents for Molecular MRI of cancer and other pathologies; Magnetic cell labeling and MRI-based cell tracking; Quantification schemes for Molecular and Cellular MRI; A path towards clinical translation for experimental Molecular and Cellular MRI paradigms

9:05 PET/CT Imaging of Inhaled Biologics for Treatment of Disease in the Lungs

Vania KenanovaVania Kenanova, Ph.D., Head, Preclinical PET/SPECT/CT Laboratory, Novartis Institute for Biomedical Research

The goal of this study was to answer if molecular weight plays a role in retention of antibodies or antibody fragments in rat lungs after intranasal delivery to the lungs. Serial PET/CT imaging of rats administered intranasally with [Zr-89] labeled Xolair (intact IgG) or anti-human FceRI Fab (antibody fragment) was utilized to generate the lung activity curves for each agent. Biodistribution and gamma counting was used to validate the imaging results. This talk will go over the study details, results and conclusions in terms of the impact that these findings may have on treatment of lung disease.

9:35 Coffee Break in the Exhibit Hall with Poster Viewing

10:20 Preclinical Ultrasound Imaging for Oncology Models

Terri SwansonTerri A. Swanson, MA, LATg, PMP, Preclinical Ultrasound, Global Science & Technology Worldwide Comparative Medicine, Pfizer

High frequency ultrasound imaging (>20MHz) can provide anatomical, functional (flow), physiological and molecular data for in vivo, non-invasive, longitudinal studies of xenograft and orthotopic tumors in rodents. It is a translational imaging technique and when combined with ultrasound contrast agents allows for micro-perfusion imaging which can be used to monitor the efficacy of anti-angiogenic compounds and for targeted imaging which can quantify vascular endothelial surface markers such as VEGFR2. These applications and their use in preclinical drug discovery programs for oncology will be discussed.

10:50 Molecular Cancer Imaging and Theranostic Probe: Toward Clinical Translation

Hisataka KobayashiHisataka Kobayashi, M.D., Ph.D., Chief Scientist, Molecular Imaging Program, National Cancer Institute

I will focus on a clinically-feasible example of “activatable” optical imaging probe, a sprayable gamma-glutamyltransferase probe, for assisting cancer detection during surgical or endoscopic procedures. Additionally, our newly developed target cancer cell-specific theranostic technology, photoimmunotherapy, which evolved from the similar concepts to imaging probe development, showed unique features including super-selective cytotoxicity, rapidly induced necrosis, that also leads super-enhanced nano-drug delivery.


Visual Sonics11:20 Utilizing Micro-Ultrasound Imaging to Assess Effects of VEGF Blockade in Tumors

Alexandra_Eichten_VisualSonicsAlexandra Eichten, Ph.D., Senior Staff Scientist, Oncology & Angiogenesis, Regeneron Pharmaceuticals

Biomarkers predicting efficacy of anti-VEGF therapies as well as effects of continued anti-VEGF blockade on tumor behavior are only partly understood. We utilized micro-ultrasound imaging to (1) investigate early perfusion changes as indicators of response and (2) use image-guided implantation to establish and study an ‘orthotopic’ CRC liver metastasis model.

Aspect Imaging11:35 Applications of Novel Compact, High-Performance MRI Platform for Pre-Clinical Phenotyping and Drug Development

Tonya Coulthard, Applications and Product Specialist, Aspect Imaging

This workshop will introduce a novel new “M-Series” compact high-performance MR imaging system that enables a broad range of in vivo imaging applications for pre-clinical phenotyping and drug development. Application examples in cancer, neurobiology, 3D toxicology and multi-modality imaging - - especially with 3D luminescence imaging - - will be shared.

11:50 Centyrins, a Protein Scaffold with Ideal Properties for Molecular Imaging Applications

Jeannie RojasJeannie Rojas, Ph.D., Director, Janssen R&D

The small size of the Centyrin molecule combined with its physical stability enables the Centyrins to be subjected to alternative delivery methods and these methods may allow for high concentrations of Centyrin molecules at the site of disease, while simultaneously lowering toxicity to non-target organs. In addition, due to the small size, Centryins may penetrate further into tissues resulting in higher sensitivity for imaging applications. In this presentation, both in vivo and in vitro data will be presented to showcase the highly desirable biophysical properties of biophysical properties of the Centyrin molecule, which make this platform ideal for imaging applications.

12:20 pm Non-Invasive in vivo Imaging of Transferrin in Breast Cancer Xenografts Using Fluorescence Lifetime FRET: Implications in the Development of Targeted Therapy

Margarida BarrosoMargarida Barroso, Ph.D., Assistant Professor, Cardiovascular Sciences, Albany Medical College

Receptor-mediated uptake of transferrin (Tfn) into human breast xenograft tumors has been demonstrated using near-infrared Förster resonance energy transfer fluorescence lifetime (FRET-FL) imaging in live mice. Near-infrared FRET-FL discriminates between soluble extracellular Tfn and receptor-bound Tfn (intracellular), increasing tumor/blood and non-tumor tissues ratio. Our data supports the quantitative accuracy and sensitivity of NIR FRET-FL imaging to be used non-invasively in live small animal models and for increasing the delivery/residency of Tfn-drug conjugates at the target site.

12:50 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:30 Session Break

(Shared Session between Tumor Models for Targeted Therapy and Imaging in Oncology) 

2:00 Chairperson’s Remarks

Paul Acton, Scientific Director and Janssen Fellow, Global Head, Molecular Imaging, Johnson & Johnson 

2:05 Translatability of Preclinical Modeling: Case Study of Development of a Targeted Therapeutic with an Imaging Companion Diagnostic

Ingrid JosephIngrid Joseph, D.V.M., Ph.D., Senior. Director, Pharmacology, Agensys, an affiliate of Astellas Pharma, Inc.

Traditional xenograft models utilize immortalized cancer cells grown on plastic that exhibit a genetic drift. Therefore, they do not represent the total genetic/epigenetic heterogeneity of the original cancers. Despite demonstrating efficacy in these models, a majority of cancer therapeutics fail in the clinic. Patient derived tumors grown as xenografts (PDXs) appear to maintain the histopathology/molecular characteristic of the original tumor. A case study utilizing PDX models better suited for targeted therapy will be discussed.

2:35 Molecular Imaging for Patient Selection and Predicting Treatment Response

Paul ActonPaul Acton, Scientific Director and Janssen Fellow, Global Head, Molecular Imaging, Johnson & Johnson

Personalized medicine would provide the key diagnostics required to deliver more effective targeted therapies, avoiding unnecessary or ineffective treatments, and reducing side effects. This presentation will outline several approaches to developing predictive imaging biomarkers, including imaging of labeled drugs, and a novel approach to tagging biologics which allows each drug to become its own companion diagnostic.

3:05 Heparin-Reactive Peptides Preferentially Co-Localize in vivo with Extracellular Melanin – A Novel Biomarker in Metastatic Melanoma Tumors

Jonathan WallJonathan Wall, Ph.D., Professor of Medicine, Human Immunology and Cancer Program; Director, Amyloid and Preclinical Molecular Imaging Laboratory, University of Tennessee Graduate School of Medicine

Melanoma is the most deadly form of skin cancer with >70,000 individuals diagnosed in 2011 in the USA. During a routine histochemical screen of biotinylated heparin-reactive peptides with a tumor tissue array, we identified certain reagents that preferentially bound melanocytic melanoma tumors. We have now demonstrated peptide reactivity, by using SPECT/CT imaging, co-localization of the peptides with B16F10 murine “metastatic” melanoma tumors within the mouse lung.

Jackson Laboratory3:35 Preclinical and Clinical Applications of Patient Derived Xenograft (PDX) Models

Yan Yang, Director, Lab Operations in vivo Services, The Jackson Laboratory

The Jackson Laboratory has established a unique collaboration with over 20 clinical centers to advance cancer treatment. Patient tumors transplanted into the NSG mouse are being screened with SOC and experimental therapeutics for preclinical research or the refinement of patient treatment regimens.

Biomodels4:05 Modeling Human Cancer: A Multifaceted Approach to Pre-Clinical Development

Maria L. Mancini, Ph.D., Prinicipal Investigator, Biomodels LLC.

There are a number of key points to consider when designing therapeutics for the treatment of human cancers. Tumor heterogeneity, stromal contribution, immune response, and treatment resistant sub-populations are all potential confounds that complicate the assessment of novel therapeutic strategies in a pre-clinical setting. Only recently have efforts been directed at treating resistant cell populations (often termed cancer stem cells).  In order to study these populations, Biomodels developed a multi-faceted approach to evaluate novel therapeutics.

5:00 Plenary Keynote Presentation

Christopher AustinCatalyzing Translational Innovation

Christopher P. Austin, M.D., Director, National Center  for Advancing, Translational Sciences, National Institutes of Health


6:00 Welcome Reception in the Exhibit Hall with Poster Viewing

7:00 Close of Day

Day 1 | Day 2 | Oncology Brochure 

Five Programs Dedicated to Preclinical Models in Oncology at World Pharma Congress 2014 

Despite tremendous progress in our understanding of cancer biology, most novelanticancer therapies fail in Phase III clinical trials. Can we break this paradigm with more predictive preclinical studies? Join pharmaceutical, biotech and academic stakeholders May 21-23 in Boston, for interactive sessions, panel discussions and short courses all geared toward providing opportunities for active networking and collaborating, while gaining strategic insights into solutions for increasing the reproducibility and predictability of preclinical cancer studies.

Suggested Event Package:

May 20

Pre-Conference Short Course*

Computational Modeling of Cancer Genomics 

May 22-23

Pre-Conference Short Course*

How To Best Utilize Organotypic 3D Cell Cultures Assays In Oncology 

* Separate registration required